EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Tumor-associated autoantibodies (AAbs) are biomarkers for lung cancer.
• The EarlyCDT®-Lung test aids early lung cancer detection in high-risk groups.
• Improving test specificity enhances cost-effectiveness and reduces false positives.

Purpose of the Study:

• To evaluate the diagnostic performance of a seven-autoantibody (AAb) panel versus a six-AAb panel for lung cancer detection.
• To assess the impact of panel composition on sensitivity and specificity in lung cancer patients and at-risk populations.

Main Methods:

• AAbs to six or seven specific antigens were measured in 235 lung cancer patients and matched controls.
• The panels' sensitivity and specificity were compared in two prospective studies of 776 and 836 individuals at increased risk for lung cancer.
• Performance was analyzed by cancer type, stage, and population risk.

Main Results:

• The seven-AAb panel demonstrated higher specificity (91%, adjusted to 93%) than the six-AAb panel (89%).
• In at-risk populations, the seven-AAb panel increased specificity from 82% to 90% without significantly altering sensitivity.
• The seven-AAb assay achieved an overall accuracy of 92% with a positive predictive value (PPV) of 1 in 8.

Conclusions:

• A seven-autoantibody panel significantly enhances the specificity of lung cancer detection tests.
• The expanded panel improves the accuracy and reliability of early lung cancer screening in high-risk individuals.
• This advancement offers a more cost-effective and less anxiety-provoking approach to lung cancer early detection.